Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum-β-Lactamase-Producing Escherichia coli

被引：75

作者：

Auer, Simon ^{[1
]}

Wojna, Alexandra ^{[2
]}

Hell, Markus ^{[1
]}

机构：

[1] Salzburg Med Univ, Dept Hosp Epidemiol & Infect Control, A-5020 Salzburg, Austria

[2] Private Labs Dr Mustafa Dr Richter, Salzburg, Austria

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2010年 / 54卷 / 09期

关键词：

IN-VITRO ACTIVITY; CTX-M; FOSFOMYCIN; ERTAPENEM; ENTEROBACTERIACEAE; ANTIMICROBIALS; CORESISTANCE;

D O I：

10.1128/AAC.01760-09

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

An increase in extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli has been observed in outpatient settings. Consequently, 100 ESBL-positive E. coli isolates from ambulatory patients with clinically confirmed urinary tract infections were collected by a single laboratory between October 2004 and January 2008. Antimicrobial susceptibility testing was carried out using the oral antibiotics fosfomycin, pivmecillinam, and nitrofurantoin and the parenteral antibiotic ertapenem. Susceptibility rates indicate that fosfomycin (97%), nitrofurantoin (94%), and pivmecillinam (85%) could be considered important oral treatment options.

引用

页码：4006 / 4008

页数：3

共 22 条

[1] In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics [J].

Alhambra, A ;

Cuadros, JA ;

Cacho, J ;

Gómez-Garcés, JL ;

Alós, JI .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (06) :1090-1094

[2] Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat [J].

Bradford, PA .

CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (04) :933-951

[3]

Chaudhary U, 2004, Indian J Med Microbiol, V22, P75

[4] Activity of fosfomycin against extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae [J].

de Cueto, Marina ;

Hernandez, Jose R. ;

Lopez-Cerero, Lorena ;

Morillo, Concepcin ;

Pascual, Alvaro .

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2006, 24 (10) :613-616

[5] Fosfomycin in a single dose versus a 7-day course of amoxicillin-clavulanate for the treatment of asymptomatic bacteriuria during pregnancy [J].

Estebanez, A. ;

Pascual, R. ;

Gil, V. ;

Ortiz, F. ;

Santibanez, M. ;

Perez Barba, C. .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2009, 28 (12) :1457-1464

[6] Other antimicrobials of interest in the era of extended-spectrum β-lactamases:: fosfomycin, nitrofurantoin and tigecycline [J].

Garau, J. .

CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 :198-202

[7] Pivmecillinam - therapy of choice for lower urinary tract infection [J].

Graninger, W .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 :S73-S78

[8] CTX-M: changing the face of ESBLs in Europe [J].

Livermore, David M. ;

Canton, Rafael ;

Gniadkowski, Marek ;

Nordmann, Patrice ;

Rossolini, Gian Maria ;

Arlet, Guillaume ;

Ayala, Juan ;

Coque, Teresa M. ;

Kern-Zdanowicz, Izabela ;

Luzzaro, Francesco ;

Poirel, Laurent ;

Woodford, Neil .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (02) :165-174

[9] Dissemination in Portugal of CTX-M-15-, OYA-1-, and TEM-1-producing Enterobacteriaceae strains containing the aac(6′)-Ib-cr gene, which encodes an aminoglycoside- and fluoroquinolone-modifying enzyme [J].

Machado, Elisabete ;

Coque, Teresa M. ;

Canton, Rafael ;

Baquero, Fernando ;

Sousa, Joao Carlos ;

Peixe, Luisa .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (09) :3220-3221

[10] Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms [J].

Mody R.M. ;

Erwin D.P. ;

Summers A.M. ;

Carrero H.A. ;

Selby E.B. ;

Ewell A.J. ;

Moran K.A. .

Annals of Clinical Microbiology and Antimicrobials, 6 (1)

← 1 2 3 →